Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
CADILA HEALTHCARE | BIOCON | CADILA HEALTHCARE/ BIOCON |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.2 | 32.4 | 77.7% | View Chart |
P/BV | x | 4.4 | 3.9 | 114.3% | View Chart |
Dividend Yield | % | 0.8 | 0.3 | 307.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
BIOCON Mar-19 |
CADILA HEALTHCARE/ BIOCON |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 707 | 49.8% | |
Low | Rs | 207 | 554 | 37.3% | |
Sales per share (Unadj.) | Rs | 139.2 | 91.9 | 151.5% | |
Earnings per share (Unadj.) | Rs | 11.8 | 16.7 | 70.4% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 24.2 | 76.8% | |
Dividends per share (Unadj.) | Rs | 3.50 | 1.00 | 350.0% | |
Dividend yield (eoy) | % | 1.3 | 0.2 | 789.9% | |
Book value per share (Unadj.) | Rs | 101.4 | 101.6 | 99.7% | |
Shares outstanding (eoy) | m | 1,023.74 | 600.00 | 170.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 6.9 | 29.3% | |
Avg P/E ratio | x | 23.7 | 37.7 | 62.9% | |
P/CF ratio (eoy) | x | 15.0 | 26.1 | 57.7% | |
Price / Book Value ratio | x | 2.8 | 6.2 | 44.4% | |
Dividend payout | % | 29.8 | 6.0 | 497.1% | |
Avg Mkt Cap | Rs m | 286,033 | 378,330 | 75.6% | |
No. of employees | `000 | 13.4 | 6.1 | 218.6% | |
Total wages/salary | Rs m | 24,145 | 11,653 | 207.2% | |
Avg. sales/employee | Rs Th | 10,632.7 | 8,994.3 | 118.2% | |
Avg. wages/employee | Rs Th | 1,801.2 | 1,900.7 | 94.8% | |
Avg. net profit/employee | Rs Th | 898.5 | 1,635.3 | 54.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 55,144 | 258.5% | |
Other income | Rs m | 1,139 | 1,444 | 78.9% | |
Total revenues | Rs m | 143,670 | 56,588 | 253.9% | |
Gross profit | Rs m | 24,198 | 15,883 | 152.4% | |
Depreciation | Rs m | 6,965 | 4,478 | 155.5% | |
Interest | Rs m | 3,418 | 709 | 482.1% | |
Profit before tax | Rs m | 14,954 | 12,140 | 123.2% | |
Minority Interest | Rs m | 288 | 9 | 3,200.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | 2,123 | 150.6% | |
Profit after tax | Rs m | 12,044 | 10,026 | 120.1% | |
Gross profit margin | % | 17.0 | 28.8 | 58.9% | |
Effective tax rate | % | 21.4 | 17.5 | 122.3% | |
Net profit margin | % | 8.5 | 18.2 | 46.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 48,228 | 180.7% | |
Current liabilities | Rs m | 82,694 | 30,376 | 272.2% | |
Net working cap to sales | % | 3.1 | 32.4 | 9.7% | |
Current ratio | x | 1.1 | 1.6 | 66.4% | |
Inventory Days | Days | 71 | 68 | 104.6% | |
Debtors Days | Days | 94 | 86 | 109.7% | |
Net fixed assets | Rs m | 133,236 | 64,130 | 207.8% | |
Share capital | Rs m | 1,024 | 3,000 | 34.1% | |
"Free" reserves | Rs m | 102,733 | 57,980 | 177.2% | |
Net worth | Rs m | 103,757 | 60,980 | 170.1% | |
Long term debt | Rs m | 32,146 | 15,766 | 203.9% | |
Total assets | Rs m | 236,866 | 121,924 | 194.3% | |
Interest coverage | x | 5.4 | 18.1 | 29.7% | |
Debt to equity ratio | x | 0.3 | 0.3 | 119.8% | |
Sales to assets ratio | x | 0.6 | 0.5 | 133.0% | |
Return on assets | % | 6.5 | 8.8 | 74.1% | |
Return on equity | % | 11.6 | 16.4 | 70.6% | |
Return on capital | % | 13.7 | 16.8 | 82.0% | |
Exports to sales | % | 0 | 28.1 | 0.0% | |
Imports to sales | % | 0 | 18.9 | 0.0% | |
Exports (fob) | Rs m | NA | 15,506 | 0.0% | |
Imports (cif) | Rs m | NA | 10,399 | 0.0% | |
Fx inflow | Rs m | 52,752 | 15,506 | 340.2% | |
Fx outflow | Rs m | 14,504 | 10,399 | 139.5% | |
Net fx | Rs m | 38,248 | 5,107 | 748.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 11,546 | 217.0% | |
From Investments | Rs m | -10,123 | -7,138 | 141.8% | |
From Financial Activity | Rs m | -10,942 | -2,417 | 452.7% | |
Net Cashflow | Rs m | 3,989 | 2,103 | 189.7% |
Indian Promoters | % | 74.8 | 40.4 | 185.1% | |
Foreign collaborators | % | 0.0 | 20.6 | - | |
Indian inst/Mut Fund | % | 8.3 | 8.4 | 98.8% | |
FIIs | % | 5.9 | 10.7 | 55.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 19.9 | 55.3% | |
Shareholders | 44,069 | 109,995 | 40.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CADILA HEALTHCARE With: ALEMBIC PHARMA STRIDES PHARMA SCIENCE J.B.CHEMICALS ASTRAZENECA PHARMA DIVIS LABORATORIES
Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Asian share markets are trading on a mixed note tracking a mixed Wall Street session following a big downturn in tech shares.
For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
This could be the biggest wealth creator of the decade.
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More